This is an aggregated industry headline. Read the full story at BioPharma Dive →
Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.
By BioPharma Dive
· Jun 11, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
An independent research firm is reviewing data on Amgen's Tavneos as the company prepares for a hearing with t…
The WeekFierceBiotech ↗
Boehringer Ingelheim's Hernexeos has nabbed a companion diagnostic from Guardant Health after the FDA cleared …
The WeekBriefing
The Trump administration proposed changes aimed at closing a loophole in Medicare’s drug price negotiation fra…